← Leaderboards
Helena Knotkova
Weill Medical Coll Of Cornell Univ
$3,717,431
Attributed
$7,434,861
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,434,861 · 2
By mechanism
R01$7,434,861 · 2
Top collaborators
- Joe Verghese5 shared
- Manney Carrington Reid2 shared
Most similar at Weill Medical Coll Of Cornell Univ
Same institution · by research overlap
- Manney Carrington Reid$15,232,004
- James E Galvin$66,836,874
- Roy M Gulick$56,577,103
- Kelly McConnell$2,203,420
- Yuhua Bao$5,650,344
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposQuality Of LifeClient SatisfactionPharmaceutical PreparationsPrimary OutcomeProtocols DocumentationHealthcare SystemsFollow-UpParticipantNeuroregulationPost InterventionPrevalenceRandomizedProceduresAdherenceCharacteristicsDepressed MoodDevicesMinimal RiskInnovationCognitiveMoodsAdverse EffectsSecondary Outcome
Grant awards (7)
Non-Invasive Home Neurostimulation for Mild to Moderate Alzheimer's Disease: Double-Blind, Sham Controlled Randomized Clinical Trial$1,039,233
R01 · FY2024 · AG
Non-Invasive Home Neurostimulation for Mild to Moderate Alzheimer's Disease: Double-Blind, Sham Controlled Randomized Clinical Trial$1,350,687
R01 · FY2023 · AG
Delivery of an At-Home Nonpharmacologic Intervention (Transcranial Neurostimulation) to Mitigate Pain in Patients with End Stage Kidney Disease Receiving Hemodialysis$578,029
R01 · FY2023 · DK
Non-Invasive Home Neurostimulation for Mild to Moderate Alzheimer's Disease: Double-Blind, Sham Controlled Randomized Clinical Trial$1,350,687
R01 · FY2022 · AG
Delivery of an At-Home Nonpharmacologic Intervention (Transcranial Neurostimulation) to Mitigate Pain in Patients with End Stage Kidney Disease Receiving Hemodialysis$630,815
R01 · FY2022 · DK
Non-Invasive Home Neurostimulation for Mild to Moderate Alzheimer's Disease: Double-Blind, Sham Controlled Randomized Clinical Trial$1,346,991
R01 · FY2021 · AG
Non-Invasive Home Neurostimulation for Mild to Moderate Alzheimer's Disease: Double-Blind, Sham Controlled Randomized Clinical Trial$1,138,419
R01 · FY2020 · AG